663:
InChI=1S/C204H301N51O64/c1-20-102(15)166(253-195(310)137(75-100(11)12)239-200(315)150(93-258)251-190(305)143(82-112-90-215-95-219-112)248-203(318)167(103(16)21-2)254-196(311)138(76-101(13)14)240-201(316)151(94-259)252-204(319)168(105(18)260)255-197(312)139(221-106(19)261)78-108-45-47-113(262)48-46-108)202(317)233-131(58-68-164(280)281)178(293)228-130(57-67-163(278)279)182(297)250-149(92-257)198(313)232-125(52-62-155(210)266)179(294)245-145(84-157(212)268)191(306)229-124(51-61-154(209)265)175(290)224-122(49-59-152(207)263)173(288)226-126(53-63-159(270)271)176(291)222-120(43-31-33-69-205)172(287)244-144(83-156(211)267)192(307)231-127(54-64-160(272)273)177(292)225-123(50-60-153(208)264)174(289)227-128(55-65-161(274)275)180(295)235-134(72-97(5)6)185(300)237-133(71-96(3)4)184(299)230-129(56-66-162(276)277)181(296)236-135(73-98(7)8)187(302)247-147(86-165(282)283)194(309)223-121(44-32-34-70-206)171(286)241-140(79-109-87-216-117-40-28-25-37-114(109)117)183(298)220-104(17)170(285)249-148(91-256)199(314)238-136(74-99(9)10)186(301)242-142(81-111-89-218-119-42-30-27-39-116(111)119)189(304)246-146(85-158(213)269)193(308)243-141(80-110-88-217-118-41-29-26-38-115(110)118)188(303)234-132(169(214)284)77-107-35-23-22-24-36-107/h22-30,35-42,45-48,87-90,95-105,120-151,166-168,216-218,256-260,262H,20-21,31-34,43-44,49-86,91-94,205-206H2,1-19H3,(H2,207,263)(H2,208,264)(H2,209,265)(H2,210,266)(H2,211,267)(H2,212,268)(H2,213,269)(H2,214,284)(H,215,219)(H,220,298)(H,221,261)(H,222,291)(H,223,309)(H,224,290)(H,225,292)(H,226,288)(H,227,289)(H,228,293)(H,229,306)(H,230,299)(H,231,307)(H,232,313)(H,233,317)(H,234,303)(H,235,295)(H,236,296)(H,237,300)(H,238,314)(H,239,315)(H,240,316)(H,241,286)(H,242,301)(H,243,308)(H,244,287)(H,245,294)(H,246,304)(H,247,302)(H,248,318)(H,249,285)(H,250,297)(H,251,305)(H,252,319)(H,253,310)(H,254,311)(H,255,312)(H,270,271)(H,272,273)(H,274,275)(H,276,277)(H,278,279)(H,280,281)(H,282,283)/t102-,103-,104-,105+,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,166-,167-,168-/m0/s1
621:
548:
525:
643:
CC(C)(C(=O)N(CCC(=O)O)C(=O)N(CCC(=O)O)C(=O)N(CO)C(=O)N(CCC(=O)N)C(=O)N(CC(=O)N)C(=O)N(CCC(=O)N)C(=O)N(CCC(=O)N)C(=O)N(CCC(=O)O)C(=O)N(CCCCN)C(=O)N(CC(=O)N)C(=O)N(CCC(=O)O)C(=O)N(CCC(=O)N)C(=O)N(CCC(=O)O)C(=O)N(CC(C)C)C(=O)N(CC(C)C)C(=O)N(CCC(=O)O)C(=O)N(CC(C)C)C(=O)N(CC(=O)O)C(=O)N(CCCCN)C(=O)N(Cc1cc2c1cccc2)C(=O)N(C)C(=O)N(CO)C(=O)N(CC(C)C)C(=O)N(Cc3cc4c3cccc4)C(=O)N(CC(=O)N)C(=O)N(Cc5cc6c5cccc6)C(=O)N(Cc7ccccc7)C(=O)N)NC(=O)(CC(C)C)NC(=O)(CO)NC(=O)(Cc8cnc8)NC(=O)((C)CC)NC(=O)(CC(C)C)NC(=O)(CO)NC(=O)((C)O)NC(=O)(Cc9ccc(cc9)O)NC(=O)C
31:
2465:
2453:
1199:
Su SB, Gong WH, Gao JL, Shen WP, Grimm MC, Deng X, et al. (June 1999). "T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor".
1066:, a new class of antiretroviral drugs. It was approved on the basis of two studies which compared the effect of optimized regimens of antiretroviral medication with and without the addition of enfuvirtide on serum
1850:
909:
that assists in the fusion of the viral membrane to the host cell membrane. Enfuvirtide binds to gp41 preventing the creation of an entry pore for the capsid of the virus, keeping it out of the cell.
1285:
Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, Matthews T (1995). "The
Inhibitory Activity of an HIV Type 1 Peptide Correlates with Its Ability to Interact with a Leucine Zipper Structure".
1824:
1742:
912:
Enfuvirtide is also an activator of the chemotactic factor receptor, formyl peptide receptor 1, and thereby activates phagocytes and presumably other cells bearing this receptor (see
200:
1363:
1844:
2034:
2039:
1985:
1457:
2424:
155:
1621:
942:
679:
1050:, where researchers formed a pharmaceutical company known as Trimeris. Trimeris began development on enfuvirtide in 1996 and initially designated it
1991:
2049:
1969:
1090:
2054:
2500:
2002:
1403:
53:
2024:
2008:
635:
2377:
2372:
2019:
2029:
1355:
2296:
1356:"Drugs@FDA: FDA Approved Drug Products – Fuzeon (Click on 'Approval Date(s) and History, Letters, Labels, Reviews for NDA 021481')"
1940:
1320:
De Clercq E (July 1995). "Toward
Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections".
2505:
2395:
2286:
2044:
1381:
2059:
686:
104:
1152:"A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy"
1615:
1396:
1134:
924:
Enfuvirtide is considered to be active against HIV-1 only. Low activity against HIV-2 isolates has been demonstrated
843:
700:
655:
2412:
2069:
1953:
754:(≥1% of patients) associated with enfuvirtide therapy include: injection site reactions (pain, hardening of skin,
2079:
2064:
1727:
1715:
185:
85:
1959:
1124:
1389:
1059:
543:
404:
2164:
504:
473:
2443:
2485:
1234:
Roche
Products Pty Ltd. Fuzeon (Australian Approved Product Information). Dee Why (NSW): Roche; 2005.
1098:
520:
2236:
2146:
2127:
2014:
1975:
913:
493:
2400:
1996:
141:
43:
2074:
453:
269:
261:
148:
2182:
882:-1 fusion machinery and displace them, preventing normal fusion. Drugs that disrupt fusion of
393:
2490:
2271:
2084:
1964:
1834:
1433:
906:
902:
767:
751:
328:
2154:
1980:
1829:
1587:
1150:
Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, et al. (March 2003).
831:
413:
291:
1411:
8:
2089:
1948:
1820:
1738:
1537:
1416:
934:
775:
739:
719:
715:
319:
547:
524:
1181:
835:
783:
115:
2495:
2231:
1894:
1337:
1302:
1267:
1217:
1173:
1168:
1151:
1130:
1055:
759:
353:
237:
224:
212:
77:
1185:
933:
Variable susceptibility to enfuvirtide has been observed in clinical isolates, with
901:
HIV binds to the host CD4+ cell receptor via the viral protein gp120; gp41, a viral
2256:
1329:
1294:
1257:
1209:
1163:
1063:
895:
891:
799:
711:
560:
247:
168:
63:
2430:
2457:
2332:
2291:
1451:
1047:
279:
255:
2469:
2406:
1412:
887:
868:
1213:
742:
with other antiretrovirals, in people where all other treatments have failed.
2479:
2172:
1922:
1757:
1643:
1024:
1004:
988:
802:
reactions occur infrequently (0.1–1% of patients), symptoms of which include
766:, itch; experienced by nearly all patients, particularly in the first week),
536:
1298:
22:
2226:
2216:
1797:
1787:
1605:
1562:
1557:
1552:
1514:
1494:
1424:
1271:
1221:
1177:
827:
795:
484:
163:
1341:
1306:
2352:
2327:
2266:
2251:
2246:
1910:
1877:
1792:
1772:
1567:
1547:
1526:
1441:
1262:
1245:
864:
839:
823:
71:
1333:
373:
2357:
2337:
2322:
2317:
2281:
2276:
2190:
2135:
2105:
1917:
1905:
1900:
1872:
1812:
1802:
1777:
1762:
1752:
1701:
1696:
1684:
1668:
1658:
1638:
1600:
1510:
1498:
1490:
1067:
1020:
1012:
996:
980:
938:
872:
787:
593:
384:
2367:
2347:
2342:
2312:
2241:
2221:
2110:
1867:
1782:
1767:
1690:
1663:
1653:
1648:
1595:
1572:
1485:
1058:
to complete the development of the drug. It was approved by the U.S.
992:
984:
968:
791:
735:
339:
304:
57:
953:
Enfuvirtide is a 36-amino acid peptide with the following sequence:
2362:
1747:
964:
926:
815:
779:
771:
755:
723:
433:
364:
99:
916:). The physiological significance of this activation is unknown.
620:
2261:
1807:
1577:
1284:
1016:
976:
875:
2211:
2206:
1008:
1000:
972:
956:
819:
811:
464:
30:
1521:
1028:
883:
807:
611:
444:
284:
2464:
509:
2035:
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
1480:
1468:
1246:"Resistance to enfuvirtide, the first HIV fusion inhibitor"
803:
763:
424:
2040:
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
1505:
1420:
879:
860:
708:
1986:
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide
1149:
871:, preventing uninfected cells from becoming infected. A
878:, enfuvirtide was designed to mimic components of the
2441:
1129:. Adelaide: Australian Medicines Handbook Pty Ltd.
1054:. In 1999, Trimeris entered into partnership with
2477:
1992:Dolutegravir/emtricitabine/tenofovir alafenamide
1243:
352:
2050:Emtricitabine/rilpivirine/tenofovir alafenamide
1970:Bictegravir/emtricitabine/tenofovir alafenamide
830:; and possibly more severe reactions including
327:
2055:Emtricitabine/rilpivirine/tenofovir disoproxil
1541:(Integrase strand transfer inhibitors (INSTI))
1362:. United States Food and Drug Administration.
2003:Dolutegravir/lamivudine/tenofovir alafenamide
1397:
1198:
863:-1 molecular machinery at the final stage of
2025:Efavirenz/emtricitabine/tenofovir disoproxil
2009:Dolutegravir/lamivudine/tenofovir disoproxil
1237:
492:
103:
1192:
1085:
1083:
1034:(Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH
2020:Doravirine/lamivudine/tenofovir disoproxil
1404:
1390:
546:
523:
392:
2030:Efavirenz/lamivudine/tenofovir disoproxil
1319:
1261:
1250:The Journal of Antimicrobial Chemotherapy
1167:
1118:
1116:
738:for the treatment of HIV-1 infection, in
412:
2297:Zinc finger protein transcription factor
1080:
1062:(FDA) on 13 March 2003 as the first HIV
1244:Greenberg ML, Cammack N (August 2004).
1228:
519:
372:
76:
2478:
1113:
854:
537:
218:
1385:
1122:
948:
472:
452:
231:
94:
62:
2501:Drugs developed by Hoffmann-La Roche
1287:AIDS Research and Human Retroviruses
859:Enfuvirtide works by disrupting the
167:
2045:Emtricitabine/tenofovir alafenamide
945:, however, has yet to be observed.
432:
343:
13:
2060:Emtricitabine/tenofovir disoproxil
790:, infections (including bacterial
745:
14:
2517:
1366:from the original on 28 June 2017
1003:-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-
194:
126:
2463:
2451:
2433:. Formerly or rarely used agent.
2070:Lamivudine/nevirapine/zidovudine
1954:Abacavir/dolutegravir/lamivudine
1169:10.1097/00002030-200303280-00007
577:
571:
29:
2237:Epigallocatechin gallate (EGCG)
2080:Lamivudine/tenofovir disoproxil
2065:Lamivudine/nevirapine/stavudine
919:
849:
729:
668:Key:PEASPLKKXBYDKL-FXEVSJAOSA-N
1960:Abacavir/lamivudine/zidovudine
1348:
1322:Journal of Medicinal Chemistry
1313:
1278:
1143:
583:
565:
207:
1:
1126:Australian Medicines Handbook
1073:
703:), sold under the brand name
2506:Drugs developed by Genentech
1060:Food and Drug Administration
7:
1835:Tenofovir alafenamide (TAF)
937:the result of a mutated 10
10:
2522:
1830:Tenofovir disoproxil (TDF)
1046:Enfuvirtide originated at
1041:
714:, the first of a class of
555:Chemical and physical data
2390:
2305:
2199:
2181:
2163:
2145:
2126:
2119:
2098:
1939:
1886:
1860:
1851:Discovery and development
1843:
1726:
1714:
1677:
1631:
1622:Discovery and development
1614:
1586:
1536:
1458:Discovery and development
1450:
1432:
1214:10.1182/blood.V93.11.3885
676:
651:
631:
609:
592:
559:
554:
535:
503:
483:
463:
443:
423:
403:
383:
363:
338:
318:
313:
303:
290:
278:
268:
254:
246:
184:
179:
154:
140:
114:
84:
70:
52:
42:
37:
28:
2147:Transcription inhibitors
2099:Pharmacokinetic boosters
2015:Dolutegravir/rilpivirine
1976:Cabotegravir/rilpivirine
1616:Protease Inhibitors (PI)
914:formyl peptide receptors
2431:initial regimen options
1997:Dolutegravir/lamivudine
1474:Enfuvirtide (ENF, T-20)
1452:Entry/fusion inhibitors
1299:10.1089/aid.1995.11.323
2272:Portmanteau inhibitors
2165:Translation inhibitors
2075:Lamivudine/raltegravir
1845:Non-nucleoside (NNRTI)
1803:Islatravir (EFdA, ISL)
752:adverse drug reactions
2287:Synergistic enhancers
2085:Lamivudine/zidovudine
1965:Atazanavir/cobicistat
1941:Combined formulations
1778:Zidovudine (AZT, ZDV)
1716:Reverse-transcriptase
1588:Maturation inhibitors
1123:Rossi S, ed. (2006).
941:motif in viral gp41.
907:conformational change
903:transmembrane protein
768:peripheral neuropathy
722:for the treatment of
2128:Uncoating inhibitors
1981:Darunavir/cobicistat
1821:Nucleotide analogues
1739:Nucleoside analogues
1538:Integrase inhibitors
1417:antiretroviral drugs
846:is not recommended.
832:respiratory distress
716:antiretroviral drugs
2120:Experimental agents
2090:Lopinavir/ritonavir
1949:Abacavir/lamivudine
1923:Elsulfavirine (ESV)
1758:Emtricitabine (FTC)
1644:Fosamprenavir (FPV)
1334:10.1021/jm00014a001
935:acquired resistance
905:, then undergoes a
855:Mechanism of action
826:, elevated hepatic
740:combination therapy
720:combination therapy
227:(Prescription only)
203:(Prescription only)
25:
2417:Never to phase III
1563:Elvitegravir (EVG)
1558:Dolutegravir (DTG)
1553:Cabotegravir (CAB)
1360:accessdata.fda.gov
1263:10.1093/jac/dkh330
949:Structural formula
943:Primary resistance
836:glomerulonephritis
21:
2439:
2438:
2386:
2385:
2232:Diarylpyrimidines
1935:
1934:
1931:
1930:
1911:Rilpivirine (RPV)
1895:diarylpyrimidines
1878:Delavirdine (DLV)
1773:Zalcitabine (ddC)
1730:nucleotide (NRTI)
1710:
1709:
1568:Raltegravir (RAL)
1548:Bictegravir (BIC)
1527:Fostemsavir (FTR)
1442:Lenacapavir (LEN)
1434:Capsid inhibitors
1328:(14): 2491–2517.
1101:on 8 January 2023
1056:Hoffmann-La Roche
896:fusion inhibitors
694:
693:
622:Interactive image
505:CompTox Dashboard
235:
222:
210:
198:
130:
97:
16:Chemical compound
2513:
2486:Entry inhibitors
2468:
2467:
2456:
2455:
2454:
2447:
2257:Hydroxycarbamide
2124:
2123:
1918:Doravirine (DOR)
1906:Etravirine (ETR)
1901:Dapivirine (DPV)
1873:Nevirapine (NVP)
1858:
1857:
1763:Lamivudine (3TC)
1753:Didanosine (ddI)
1724:
1723:
1697:Tipranavir (TPV)
1685:Atazanavir (ATV)
1669:Saquinavir (SQV)
1659:Nelfinavir (NFV)
1639:Amprenavir (APV)
1629:
1628:
1511:Ibalizumab (IBA)
1406:
1399:
1392:
1383:
1382:
1376:
1375:
1373:
1371:
1352:
1346:
1345:
1317:
1311:
1310:
1282:
1276:
1275:
1265:
1241:
1235:
1232:
1226:
1225:
1196:
1190:
1189:
1171:
1147:
1141:
1140:
1120:
1111:
1110:
1108:
1106:
1097:. Archived from
1095:guildlink.com.au
1087:
1064:fusion inhibitor
892:entry inhibitors
867:with the target
800:hypersensitivity
712:fusion inhibitor
690:
689:
682:
624:
604:
602:
585:
579:
573:
567:
550:
539:
528:
527:
513:
511:
496:
476:
456:
436:
416:
396:
376:
356:
346:
345:
331:
295:
233:
230:
220:
217:
209:
206:
196:
193:
171:
128:
125:
107:
96:
93:
80:
66:
33:
26:
24:
20:
2521:
2520:
2516:
2515:
2514:
2512:
2511:
2510:
2476:
2475:
2474:
2462:
2452:
2450:
2442:
2440:
2435:
2434:
2422:
2407:Clinical trials
2382:
2333:Dexelvucitabine
2301:
2292:Tre recombinase
2195:
2177:
2159:
2155:Tat antagonists
2141:
2115:
2094:
1927:
1882:
1868:Efavirenz (EFV)
1847:
1839:
1768:Stavudine (d4T)
1729:
1717:
1706:
1691:Darunavir (DRV)
1673:
1664:Ritonavir (RTV)
1654:Lopinavir (LPV)
1649:Indinavir (IDV)
1618:
1610:
1582:
1540:
1532:
1486:Maraviroc (MVC)
1454:
1446:
1428:
1413:Antiviral drugs
1410:
1380:
1379:
1369:
1367:
1354:
1353:
1349:
1318:
1314:
1283:
1279:
1242:
1238:
1233:
1229:
1208:(11): 3885–92.
1197:
1193:
1148:
1144:
1137:
1121:
1114:
1104:
1102:
1089:
1088:
1081:
1076:
1048:Duke University
1044:
1037:
1032:
960:
951:
922:
857:
852:
748:
746:Adverse effects
734:Enfuvirtide is
732:
685:
683:
680:(what is this?)
677:
672:
669:
664:
659:
658:
647:
644:
639:
638:
627:
600:
598:
588:
582:
576:
570:
531:
507:
499:
479:
459:
439:
419:
399:
379:
359:
342:
334:
293:
270:Protein binding
256:Bioavailability
248:Pharmacokinetic
242:
175:
143:
136:
117:
110:
17:
12:
11:
5:
2519:
2509:
2508:
2503:
2498:
2493:
2488:
2473:
2472:
2460:
2437:
2436:
2421:
2420:
2419:
2418:
2415:
2404:
2398:
2392:
2391:
2388:
2387:
2384:
2383:
2381:
2380:
2375:
2370:
2365:
2360:
2355:
2350:
2345:
2340:
2335:
2330:
2325:
2320:
2315:
2309:
2307:
2303:
2302:
2300:
2299:
2294:
2289:
2284:
2279:
2274:
2269:
2264:
2259:
2254:
2249:
2244:
2239:
2234:
2229:
2224:
2219:
2214:
2209:
2203:
2201:
2197:
2196:
2194:
2193:
2187:
2185:
2179:
2178:
2176:
2175:
2169:
2167:
2161:
2160:
2158:
2157:
2151:
2149:
2143:
2142:
2140:
2139:
2132:
2130:
2121:
2117:
2116:
2114:
2113:
2108:
2106:Cobicistat (c)
2102:
2100:
2096:
2095:
2093:
2092:
2087:
2082:
2077:
2072:
2067:
2062:
2057:
2052:
2047:
2042:
2037:
2032:
2027:
2022:
2017:
2012:
2006:
2000:
1994:
1989:
1983:
1978:
1973:
1967:
1962:
1957:
1951:
1945:
1943:
1937:
1936:
1933:
1932:
1929:
1928:
1926:
1925:
1920:
1915:
1914:
1913:
1908:
1903:
1890:
1888:
1884:
1883:
1881:
1880:
1875:
1870:
1864:
1862:
1855:
1841:
1840:
1838:
1837:
1832:
1816:
1815:
1810:
1805:
1800:
1795:
1790:
1785:
1780:
1775:
1770:
1765:
1760:
1755:
1750:
1748:Abacavir (ABC)
1734:
1732:
1728:Nucleoside and
1721:
1712:
1711:
1708:
1707:
1705:
1704:
1699:
1694:
1688:
1681:
1679:
1675:
1674:
1672:
1671:
1666:
1661:
1656:
1651:
1646:
1641:
1635:
1633:
1626:
1612:
1611:
1609:
1608:
1603:
1598:
1592:
1590:
1584:
1583:
1581:
1580:
1575:
1570:
1565:
1560:
1555:
1550:
1544:
1542:
1534:
1533:
1531:
1530:
1518:
1502:
1488:
1477:
1464:
1462:
1448:
1447:
1445:
1444:
1438:
1436:
1430:
1429:
1409:
1408:
1401:
1394:
1386:
1378:
1377:
1347:
1312:
1277:
1236:
1227:
1191:
1142:
1135:
1112:
1078:
1077:
1075:
1072:
1043:
1040:
1035:
1030:
958:
950:
947:
921:
918:
856:
853:
851:
848:
747:
744:
731:
728:
692:
691:
674:
673:
671:
670:
667:
665:
662:
654:
653:
652:
649:
648:
646:
645:
642:
634:
633:
632:
629:
628:
626:
625:
617:
615:
607:
606:
596:
590:
589:
586:
580:
574:
568:
563:
557:
556:
552:
551:
541:
533:
532:
530:
529:
521:DTXSID20166672
516:
514:
501:
500:
498:
497:
489:
487:
481:
480:
478:
477:
469:
467:
461:
460:
458:
457:
449:
447:
441:
440:
438:
437:
429:
427:
421:
420:
418:
417:
409:
407:
401:
400:
398:
397:
389:
387:
381:
380:
378:
377:
369:
367:
361:
360:
358:
357:
349:
347:
336:
335:
333:
332:
324:
322:
316:
315:
311:
310:
307:
301:
300:
297:
288:
287:
282:
276:
275:
272:
266:
265:
258:
252:
251:
244:
243:
241:
240:
228:
215:
204:
190:
188:
182:
181:
177:
176:
174:
173:
160:
158:
152:
151:
146:
144:administration
138:
137:
135:
134:
132:
122:
120:
112:
111:
109:
108:
90:
88:
82:
81:
74:
68:
67:
60:
50:
49:
46:
40:
39:
35:
34:
15:
9:
6:
4:
3:
2:
2518:
2507:
2504:
2502:
2499:
2497:
2494:
2492:
2489:
2487:
2484:
2483:
2481:
2471:
2466:
2461:
2459:
2449:
2448:
2445:
2432:
2429:
2426:
2416:
2414:
2411:
2410:
2408:
2405:
2402:
2399:
2397:
2394:
2393:
2389:
2379:
2376:
2374:
2371:
2369:
2366:
2364:
2361:
2359:
2356:
2354:
2351:
2349:
2346:
2344:
2341:
2339:
2336:
2334:
2331:
2329:
2326:
2324:
2321:
2319:
2316:
2314:
2311:
2310:
2308:
2306:Failed agents
2304:
2298:
2295:
2293:
2290:
2288:
2285:
2283:
2280:
2278:
2275:
2273:
2270:
2268:
2265:
2263:
2260:
2258:
2255:
2253:
2250:
2248:
2245:
2243:
2240:
2238:
2235:
2233:
2230:
2228:
2225:
2223:
2220:
2218:
2215:
2213:
2210:
2208:
2205:
2204:
2202:
2198:
2192:
2189:
2188:
2186:
2184:
2180:
2174:
2173:Trichosanthin
2171:
2170:
2168:
2166:
2162:
2156:
2153:
2152:
2150:
2148:
2144:
2137:
2134:
2133:
2131:
2129:
2125:
2122:
2118:
2112:
2111:Ritonavir (r)
2109:
2107:
2104:
2103:
2101:
2097:
2091:
2088:
2086:
2083:
2081:
2078:
2076:
2073:
2071:
2068:
2066:
2063:
2061:
2058:
2056:
2053:
2051:
2048:
2046:
2043:
2041:
2038:
2036:
2033:
2031:
2028:
2026:
2023:
2021:
2018:
2016:
2013:
2010:
2007:
2004:
2001:
1998:
1995:
1993:
1990:
1987:
1984:
1982:
1979:
1977:
1974:
1971:
1968:
1966:
1963:
1961:
1958:
1955:
1952:
1950:
1947:
1946:
1944:
1942:
1938:
1924:
1921:
1919:
1916:
1912:
1909:
1907:
1904:
1902:
1899:
1898:
1897:
1896:
1892:
1891:
1889:
1885:
1879:
1876:
1874:
1871:
1869:
1866:
1865:
1863:
1859:
1856:
1854:
1852:
1846:
1842:
1836:
1833:
1831:
1828:
1826:
1822:
1818:
1817:
1814:
1811:
1809:
1806:
1804:
1801:
1799:
1796:
1794:
1791:
1789:
1786:
1784:
1781:
1779:
1776:
1774:
1771:
1769:
1766:
1764:
1761:
1759:
1756:
1754:
1751:
1749:
1746:
1744:
1740:
1736:
1735:
1733:
1731:
1725:
1722:
1719:
1713:
1703:
1700:
1698:
1695:
1692:
1689:
1686:
1683:
1682:
1680:
1676:
1670:
1667:
1665:
1662:
1660:
1657:
1655:
1652:
1650:
1647:
1645:
1642:
1640:
1637:
1636:
1634:
1630:
1627:
1625:
1623:
1617:
1613:
1607:
1604:
1602:
1599:
1597:
1594:
1593:
1591:
1589:
1585:
1579:
1576:
1574:
1571:
1569:
1566:
1564:
1561:
1559:
1556:
1554:
1551:
1549:
1546:
1545:
1543:
1539:
1535:
1528:
1524:
1523:
1519:
1516:
1512:
1508:
1507:
1503:
1500:
1496:
1492:
1489:
1487:
1483:
1482:
1478:
1475:
1471:
1470:
1466:
1465:
1463:
1461:
1459:
1453:
1449:
1443:
1440:
1439:
1437:
1435:
1431:
1426:
1422:
1419:used against
1418:
1414:
1407:
1402:
1400:
1395:
1393:
1388:
1387:
1384:
1365:
1361:
1357:
1351:
1343:
1339:
1335:
1331:
1327:
1323:
1316:
1308:
1304:
1300:
1296:
1293:(3): 323–25.
1292:
1288:
1281:
1273:
1269:
1264:
1259:
1256:(2): 333–40.
1255:
1251:
1247:
1240:
1231:
1223:
1219:
1215:
1211:
1207:
1203:
1195:
1187:
1183:
1179:
1175:
1170:
1165:
1161:
1157:
1153:
1146:
1138:
1136:0-9757919-2-3
1132:
1128:
1127:
1119:
1117:
1100:
1096:
1092:
1086:
1084:
1079:
1071:
1069:
1065:
1061:
1057:
1053:
1049:
1039:
1033:
1026:
1022:
1019:-Ser-Leu-Trp-
1018:
1014:
1010:
1006:
1002:
999:-Gln-Gln-Glu-
998:
994:
990:
987:-Ser-Leu-Ile-
986:
982:
978:
974:
970:
966:
962:
954:
946:
944:
940:
936:
931:
929:
928:
917:
915:
910:
908:
904:
899:
897:
893:
889:
885:
881:
877:
874:
870:
866:
862:
847:
845:
841:
837:
833:
829:
828:transaminases
825:
821:
817:
813:
809:
805:
801:
797:
793:
789:
785:
781:
777:
773:
769:
765:
761:
757:
753:
743:
741:
737:
727:
725:
721:
717:
713:
710:
706:
702:
698:
688:
681:
675:
666:
661:
660:
657:
650:
641:
640:
637:
630:
623:
619:
618:
616:
613:
608:
597:
595:
591:
564:
562:
558:
553:
549:
545:
542:
540:
538:ECHA InfoCard
534:
526:
522:
518:
517:
515:
506:
502:
495:
491:
490:
488:
486:
482:
475:
471:
470:
468:
466:
462:
455:
451:
450:
448:
446:
442:
435:
431:
430:
428:
426:
422:
415:
411:
410:
408:
406:
402:
395:
391:
390:
388:
386:
382:
375:
371:
370:
368:
366:
362:
355:
351:
350:
348:
341:
337:
330:
326:
325:
323:
321:
317:
312:
308:
306:
302:
298:
296:
289:
286:
283:
281:
277:
273:
271:
267:
263:
259:
257:
253:
249:
245:
239:
229:
226:
216:
214:
205:
202:
192:
191:
189:
187:
183:
178:
170:
165:
162:
161:
159:
157:
153:
150:
147:
145:
139:
133:
124:
123:
121:
119:
113:
106:
101:
92:
91:
89:
87:
83:
79:
75:
73:
69:
65:
61:
59:
55:
51:
47:
45:
41:
38:Clinical data
36:
32:
27:
19:
2491:Hepatotoxins
2427:
2227:Cyanovirin-N
2217:Calanolide A
1893:
1887:2 generation
1861:1 generation
1848:
1819:
1798:Elvucitabine
1788:Apricitabine
1737:
1678:2 generation
1632:1 generation
1619:
1606:Fipravirimat
1520:
1515:Semzuvolimab
1504:
1495:Cenicriviroc
1479:
1473:
1467:
1455:
1368:. Retrieved
1359:
1350:
1325:
1321:
1315:
1290:
1286:
1280:
1253:
1249:
1239:
1230:
1205:
1201:
1194:
1162:(5): 691–8.
1159:
1155:
1145:
1125:
1103:. Retrieved
1099:the original
1094:
1051:
1045:
955:
952:
932:
925:
923:
920:Microbiology
911:
900:
858:
850:Pharmacology
796:eosinophilia
749:
733:
730:Medical uses
704:
696:
695:
684:
678:
485:NIAID ChemDB
474:ChEMBL525076
454:CHEBI:608828
292:Elimination
186:Legal status
180:Legal status
149:Subcutaneous
86:License data
18:
2428:recommended
2403:from market
2353:Lersivirine
2328:Capravirine
2267:Miltefosine
2252:Griffithsin
2247:Fosdevirine
1793:Censavudine
1423:(primarily
890:are termed
886:and target
844:rechallenge
840:anaphylaxis
824:hypotension
697:Enfuvirtide
605: g·mol
544:100.169.201
329:159519-65-0
314:Identifiers
105:Enfuvirtide
72:MedlinePlus
44:Trade names
23:Enfuvirtide
2480:Categories
2358:Lodenosine
2338:Droxinavir
2323:Brecanavir
2318:Atevirdine
2282:Seliciclib
2277:Scytovirin
2191:Elipovimab
2136:TRIM5alpha
1813:Stampidine
1718:inhibitors
1702:TMC-310911
1601:BMS-955176
1499:Leronlimab
1491:Vicriviroc
1074:References
1068:viral load
939:amino acid
873:biomimetic
822:, rigors,
798:. Various
788:arthralgia
776:depression
610:3D model (
594:Molar mass
414:19OWO1T3ZE
385:ChemSpider
320:CAS Number
280:Metabolism
2413:Phase III
2401:Withdrawn
2378:Telinavir
2373:Palinavir
2368:Mozenavir
2348:Emivirine
2343:Lasinavir
2313:Aplaviroc
2242:Foscarnet
2222:Ceragenin
1783:Amdoxovir
1596:Bevirimat
1573:BI 224436
1370:6 January
1105:8 January
1091:"Product"
991:-Glu-Ser-
794:) and/or
792:pneumonia
778:, cough,
736:indicated
305:Excretion
299:3.8 hours
294:half-life
142:Routes of
116:Pregnancy
64:Monograph
58:Drugs.com
2496:Peptides
2458:Medicine
2363:Loviride
1364:Archived
1272:15231762
1222:10339497
1186:32014873
1178:12646792
927:in vitro
816:vomiting
784:anorexia
780:dyspnoea
772:insomnia
756:erythema
724:AIDS/HIV
718:used in
707:, is an
687:(verify)
394:16743716
365:DrugBank
354:16130199
156:ATC code
131: B2
118:category
100:DailyMed
2470:Viruses
2444:Portals
2262:KP-1461
1808:Racivir
1578:MK-2048
1342:7543152
1307:7786578
1042:History
876:peptide
838:and/or
760:nodules
750:Common
561:Formula
374:DB00109
340:PubChem
309:unknown
260:84.3% (
211::
172:)
166: (
164:J05AX07
102::
78:a603023
2396:WHO-EM
2212:BIT225
2207:Abzyme
2138:(gene)
1825:NtRTIs
1720:(RTIs)
1340:
1305:
1270:
1220:
1184:
1176:
1133:
865:fusion
820:chills
812:nausea
705:Fuzeon
636:SMILES
494:059486
465:ChEMBL
434:D02499
238:℞-only
236:
223:
213:℞-only
199:
98:
48:Fuzeon
2200:Other
2183:BNAbs
1743:NRTIs
1522:gp120
1202:Blood
1182:S2CID
1023:-Trp-
884:virus
808:fever
764:cysts
656:InChI
612:JSmol
445:ChEBI
285:Liver
2425:DHHS
1481:CCR5
1469:gp41
1372:2019
1338:PMID
1303:PMID
1268:PMID
1218:PMID
1174:PMID
1156:AIDS
1131:ISBN
1107:2023
1052:T-20
888:cell
869:cell
804:rash
603:.945
425:KEGG
405:UNII
250:data
54:AHFS
1506:CD4
1425:J05
1421:HIV
1330:doi
1295:doi
1258:doi
1210:doi
1164:doi
1025:Phe
1021:Asn
1017:Ala
1013:Trp
1009:Lys
1005:Asp
1001:Lys
997:Asn
993:Gln
989:Glu
985:His
981:Ile
977:Leu
973:Ser
969:Thr
965:Tyr
894:or
880:HIV
861:HIV
709:HIV
701:INN
601:491
575:301
569:204
510:EPA
344:CID
274:92%
225:POM
169:WHO
2482::
2409::
1513:,
1497:,
1493:,
1415::
1358:.
1336:.
1326:38
1324:.
1301:.
1291:11
1289:.
1266:.
1254:54
1252:.
1248:.
1216:.
1206:93
1204:.
1180:.
1172:.
1160:17
1158:.
1154:.
1115:^
1093:.
1082:^
1070:.
1038:)
1029:NH
961:CO
957:CH
930:.
898:.
842:–
834:,
818:,
814:,
810:,
806:,
786:,
782:,
774:,
770:,
762:,
758:,
726:.
587:64
581:51
262:SC
232:US
219:UK
208:CA
201:S4
195:AU
127:AU
95:US
2446::
2423:°
2011:°
2005:°
1999:°
1988:°
1972:°
1956:°
1853:)
1849:(
1827::
1823:/
1745::
1741:/
1693:°
1687:°
1624:)
1620:(
1529:)
1525:(
1517:)
1509:(
1501:)
1484:(
1476:)
1472:(
1460:)
1456:(
1427:)
1405:e
1398:t
1391:v
1374:.
1344:.
1332::
1309:.
1297::
1274:.
1260::
1224:.
1212::
1188:.
1166::
1139:.
1109:.
1036:2
1031:2
1027:-
1015:-
1011:-
1007:-
995:-
983:-
979:-
975:-
971:-
967:-
963:-
959:3
699:(
614:)
599:4
584:O
578:N
572:H
566:C
512:)
508:(
264:)
234::
221::
197::
129::
56:/
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
